Fierce Pharma
AUGUST 1, 2024
Like clockwork, another lawsuit challenging the constitutionality of the Inflation Reduction Act's (IRA's) price-setting measures has been shot down in the courts. | The ruling from the New Jersey federal court marks the latest in a string of rejections as various drugmakers have taken to the courts to fight the drug pricing legislation.
MedCity News
AUGUST 1, 2024
A new report showed that financial margins have leveled off for both hospitals and physician groups in recent months. However, costs for drugs and labor continue to climb. The post Providers’ Finances Are Steady, But Cost Pressures Still Loom appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 1, 2024
Like many other biopharma companies, Kyowa Kirin is in restructuring mode. | Kyowa Kirin is planning “a significant reduction” in its small molecule drug discovery research activities and will trim certain manufacturing roles. The company is also divesting its Chinese operations as part of a larger restructuring in the Asia-Pacific region.
MedCity News
AUGUST 1, 2024
Huma has spent 10 years perfecting its technology stack and now it wants others to build off of its expertise, says the company’s chief medical officer. The post Huma’s Evolution From Patient Monitoring Apps to Cloud Platform With AI Chops appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
AUGUST 1, 2024
Two weeks ago, Novartis CEO Vas Narasimhan referred to the initial wave of drug pricing effects tied to the Inflation Reduction Act (IRA) as “manageable.” | Novartis has filed a lawsuit against the FDA, claiming that the U.S. regulator’s approval of a generic version of Entresto is unlawful. The complaint comes a week after the FDA approved an Entresto generic from MSN Laboratories.
MedCity News
AUGUST 1, 2024
Healthcare organizations can significantly improve their resilience against ransomware attacks by implementing proactive protection, continuous monitoring, and rapid recovery strategies. Proactive protection, continuous monitoring, and rapid recovery strategies are key. The post Nearly Every Large Healthcare Organization Uses Microsoft Active Directory: Here’s How to Secure It to Safeguard Against Escalating Ransomware Attacks appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 1, 2024
Here is a list of some of the biggest funding rounds from health tech companies that were announced in July. The post 5 Notable Health Tech Funding Announcements in July appeared first on MedCity News.
Fierce Pharma
AUGUST 1, 2024
The post-pandemic period has posed serious challenges for financial forecasters at the top mRNA vaccine makers, as evidenced by Pfizer's
pharmaphorum
AUGUST 1, 2024
Bayer files elinzanetant as a non-hormonal treatment for menopausal symptoms, with Astellas' first-to-market Veozah in its sights
Fierce Pharma
AUGUST 1, 2024
With U.S. sales of $304 million during the second quarter, Regeneron’s high-dose version of Eylea came up just short of analyst projections. | The launch of Regeneron's Eylea HD has helped the Eylea franchise to a rebound after U.S. sales had declined in each of the previous three quarters. Additionally, Regeneron reported that its FDA decision date on its application for approval of multiple myeloma therapy linvoseltamab is likely to be delayed because of a manufacturing issue.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
AUGUST 1, 2024
The UK NICE has recommended BeiGene’s Zanubrutinib for marginal zone lymphoma (MZL) for use on the National Health Service (NHS).
Fierce Pharma
AUGUST 1, 2024
A year and a half after unveiling a strategic review of its biosimilars franchise as part of a reprioritization, Biogen has decided to keep the business as the company continues to navigate a busin | A year and a half after unveiling a strategic review of its biosimilars franchise, Biogen has decided to keep the business as the company continues to navigate a business turnaround with Leqembi leading the way.
pharmaphorum
AUGUST 1, 2024
UK DNA/RNA sequencing specialist Oxford Nanopore raises £80m in a share issue backed with £50m from Novo Holdings
Fierce Pharma
AUGUST 1, 2024
Despite missing the primary endpoint in a pediatric study, Agios says it remains steadfast in working to grow the reach of its pyruvate kinase (PK) activation franchise. | The trial in PK-deficient children who receive regular transfusions didn't meet its primary endpoint based on an analysis that incorporated response data from a prior adult study.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
AUGUST 1, 2024
Otsuka Pharma agrees a $1.
PharmaTimes
AUGUST 1, 2024
Combined, ovarian and breast cancer affect over 60,000 women in the UK every year
PharmaVoice
AUGUST 1, 2024
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
MedCity News
AUGUST 1, 2024
Otsuka Pharmaceutical is acquiring Jnana Therapeutics, whose lead drug is a potential treatment for the rare metabolic disorder phenylketonuria (PKU). Jnana’s drug could provide an alternative to two FDA-approved PKU medicines from BioMarin Pharmaceutical. The post Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug appeared first on MedCity News.
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's S4V vaccine candidate, and promising undisclosed regulatory, development and sales-based milestone payments.
Pharmaceutical Technology
AUGUST 1, 2024
The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s phenylketonuria therapy to its portfolio.
PharmaTimes
AUGUST 1, 2024
The collaboration aims to develop new medicines to reduce chronic kidney disease in Scotland
Pharmaceutical Technology
AUGUST 1, 2024
Takeda has reported a revenue of Y1,208bn for Q1 FY2024, a 14.1% increase from Y1,058bn in the corresponding period of FY2023.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTech
AUGUST 1, 2024
In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts from Biosynth and the University of Maryland about biopharmaceutical drug development and manufacturing.
Pharmaceutical Technology
AUGUST 1, 2024
Valneva and LimmaTech have signed a deal to potentially develop the first marketed shigellosis vaccine.
PM360
AUGUST 1, 2024
CHICAGO – Aug. 1, 2024 – EVERSANA , a leading provider of global commercial services to the life sciences industry, today introduced TEDAVI , the pharmaceutical and life science industry’s premier content transformation hub built to streamline content production, enable personalization at scale and accelerate time-to-market for brand assets while ensuring compliance.
Pharmacy Times
AUGUST 1, 2024
The findings provide guidance for clinicians and patients when navigating therapeutic options to establish treatment plans.
Veeva
AUGUST 1, 2024
In an age where customers are split across in-person and digital channels, adopting an optimized segmentation and targeting strategy can help sales representatives better understand their target audience’s preferences and optimize the way they engage with customers. To effectively engage with healthcare professionals (HCPs), it is crucial to understand their preferences and needs.
Pharmacy Times
AUGUST 1, 2024
Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.
PharmExec
AUGUST 1, 2024
Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different doses.
Pharmaceutical Technology
AUGUST 1, 2024
HilleVax’s norovirus vaccine HIL-214 failed to meet key endpoints in its Phase IIb trial in infants prompting the company to let go of 41 employees.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
306 
Let's personalize your content